NCT04493541View on ClinicalTrials.gov

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 26, 2020

Primary Completion Date

April 21, 2023

Study Completion Date

April 21, 2023

Conditions
Lupus Erythematosus, Cutaneous
Interventions
DRUG

BMS-986256

Specified Dose on Specified Days

OTHER

BMS-986256 Placebo

Specified Dose on Specified Days

Trial Locations (1)

10117

Local Institution - 0001, Berlin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY